430 Dose finding of inecalcitol, a new VDR agonist, in combination with docetaxel–prednisone regimen for castrate-resistant prostate cancer (HRPC) patients (pts)

Authors :: J. Medioni
T. Maurina
J.M. Rodier
S. Renaux
J-M Ferrero
G. Deplanque
G. Allyon
Eric Raymond
Stéphane Oudard
J.F. Dufour-Lamartinie
Source :: European Journal of Cancer Supplements. 8:136
Publication Year :: 2010
Publisher :: Elsevier BV, 2010.

Subjects :: Oncology
Agonist
Cancer Research
medicine.medical_specialty
business.industry
medicine.drug_class
Castrate-resistant prostate cancer
Calcitriol receptor
Inecalcitol
Dose finding
Internal medicine
Medicine
Docetaxel-Prednisone Regimen
business

Full Text Access

Tools